Wedbush Reduces Earnings Estimates for Compass Therapeutics

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Equities research analysts at Wedbush decreased their Q3 2025 earnings per share estimates for Compass Therapeutics in a note issued to investors on Tuesday, April 1st. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of ($0.13) for the quarter, down from their previous estimate of ($0.10). Wedbush has a "Outperform" rating and a $8.00 price target on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Compass Therapeutics' Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.42 EPS.

A number of other analysts also recently issued reports on CMPX. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 1st. Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. Guggenheim restated a "buy" rating and issued a $12.00 target price on shares of Compass Therapeutics in a research report on Wednesday, April 2nd. Jefferies Financial Group increased their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, February 10th. Finally, Leerink Partners upgraded shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $4.00 to $6.00 in a report on Wednesday, April 2nd. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $13.38.

Remove Ads

Compass Therapeutics Stock Performance

Compass Therapeutics stock traded up $0.01 during mid-day trading on Friday, hitting $1.58. 958,329 shares of the company traded hands, compared to its average volume of 821,648. Compass Therapeutics has a one year low of $0.77 and a one year high of $4.08. The stock has a market cap of $217.80 million, a price-to-earnings ratio of -4.26 and a beta of 1.40. The stock has a fifty day moving average price of $2.73 and a 200-day moving average price of $2.11.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

Insiders Place Their Bets

In other news, insider Jonathan Anderman bought 20,000 shares of the company's stock in a transaction dated Monday, April 7th. The stock was bought at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the acquisition, the insider now owns 21,000 shares in the company, valued at approximately $32,340. This trade represents a 2,000.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 28.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new stake in shares of Compass Therapeutics in the 4th quarter worth approximately $35,000. Tang Capital Management LLC lifted its stake in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after acquiring an additional 4,087,005 shares during the period. ProShare Advisors LLC boosted its holdings in Compass Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after acquiring an additional 9,451 shares in the last quarter. MPM Bioimpact LLC increased its position in Compass Therapeutics by 51.9% during the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after purchasing an additional 2,926,002 shares during the period. Finally, Enavate Sciences GP LLC purchased a new position in Compass Therapeutics during the 4th quarter valued at $11,293,000. Hedge funds and other institutional investors own 68.43% of the company's stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.